News on research and diagnostics in autoimmune disorders including rheumatoid arthritis, lupus, multiple sclerosis, and more.
The new company will develop microbiome diagnostics for multiple indications including inflammatory bowel disease and liver disorders.
The researchers plan to profile patients with both Adaptive Biotechnologies' ImmunoSeq platform and 10x Genomics' single-cell immune repertoire profiling technology.
The firm's recent funding round will support its CLIA-certified laboratory that opened last year and the launch of its first RNA-based diagnostic test.
The algorithm identifies proteins in blood samples taken after bone marrow transplants that predict patients at risk for severe graft-versus-host disease.
The project aims to elucidate markers of response and non-response to current treatment regimens, and to identify new therapies.
